Search

Xcellent idea

LOCAL medical devices company Xcell Diagnostics has formalised its acquisition of local business InfaMed and the patented Funhaler.

InfaMed has developed a small volume spacer device for children who suffer from asthma, named the Funhaler.

The fully-approved acquisition of shares in InfaMed, announced at this week’s general meeting, makes it a wholly owned subsidiary of Xcell, according to managing director Barry Fehlberg.

Clinical trials of the Funhaler are currently under way at the University of Western Australia with the support of a $450,000 Federal Government grant.

Xcell is also involved in research on a skin cancer analysis, which involves funding skin cancer research utilising diffuse reflectance spectroscopy at the UWA.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

BNIQ sponsored byECU School of Business and Law

Students

6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE10,000
10th-The University of Notre Dame Australia6,708
47 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer